Biotech Stocks Rally in After-Hours Trading: Cassava, Helius, Werewolf, Aytu, and Equillium Drive Late Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Source: NASDAQ.COM
Cassava Sciences Surge: Cassava Sciences (SAVA) saw a 37.1% increase in after-hours trading, driven by renewed interest in its investigational drug simufilam for TSC-related epilepsy, following positive preclinical data and leadership changes.
Helius Medical Technologies Rebound: Helius Medical Technologies (HSDT) rose 15.67% after announcing a $500 million private placement to pivot towards a Solana-focused treasury vehicle, while also advancing its medical device pipeline.
Werewolf Therapeutics Gains: Werewolf Therapeutics (HOWL) increased by 9.78% in after-hours trading, supported by interest in its INDUKINE platform and upcoming interim data from its lead candidate targeting advanced solid tumors.
Aytu BioPharma and Equillium Updates: Aytu BioPharma (AYTU) rose 7.63% ahead of its fiscal results announcement, while Equillium (EQ) gained 10.34% after securing financing to advance its novel drug EQ504 and progressing its lead candidate in clinical trials.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on SAVA
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cassava Technologies and AXON Networks Form Strategic Partnership
- Strategic Partnership Announcement: Cassava Technologies and AXON Networks unveiled their strategic partnership at the Counder Conference in Cape Town, aiming to co-develop Africa's first end-to-end Operator-as-a-Service (OaaS) platform to drive digital transformation through AI-driven network solutions.
- Infrastructure Enhancement: The OaaS platform will leverage Cassava's extensive 110,000 km fiber network to deliver secure, high-speed data infrastructure, significantly enhancing the agility and intelligence of mobile network operators and ISPs, thereby fostering economic growth and innovation.
- AI-Driven Digital Twin Technology: AXON's Digital Twin technology will transform networks into self-learning, self-optimizing systems, reducing operational complexity, accelerating service delivery, and ensuring resilient connectivity at scale, thus providing customers with more efficient service experiences.
- Market Potential Unleashed: This collaboration will not only provide a robust digital foundation for African businesses but also promote widespread AI adoption, helping enterprises gain competitive advantages in the global market and showcasing Africa's immense potential in the digital economy.
Continue Reading
Cassava Sciences Faces Shareholder Rights Investigation by Halper Sadeh LLC
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Cassava Sciences, Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Cassava stock may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could directly affect shareholder financial interests and company transparency.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, thereby enhancing management efficiency and transparency, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide who have fallen victim to securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
Continue Reading